Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ pharmacology
Bone Marrow
/ immunology
Breast Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
Female
Humans
Lymphocyte Subsets
/ pathology
Lymphocytes, Tumor-Infiltrating
/ pathology
Middle Aged
Neoadjuvant Therapy
Neoplasm, Residual
Prognosis
Tumor Microenvironment
/ drug effects
B cells
Breast cancer
Disseminated tumor cells
Minimal residual disease
Neoadjuvant chemotherapy
T cells
Tumor microenvironment
Tumor-infiltrating lymphocytes
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
04 Feb 2019
04 Feb 2019
Historique:
received:
07
07
2018
accepted:
25
01
2019
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
31
8
2019
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) are described as an important immune modulator in the tumor microenvironment and are associated with breast cancer (BC) outcome. The spatial analysis of TILs and TIL subtype distribution at the invasive tumor front (ITF) and the tumor center (TC) might provide further insights into tumor progression. We analyzed core biopsies from 87 pre-therapeutic BC patients for total TILs and the following subtypes: CD3+, CD4+, CD8+, CD20+ and CD68+ cells in correlation to clinicopathological parameters and disseminated tumor cells (DTCs) in the bone marrow. TILs and TIL subtypes showed significantly different spatial distribution among both tumor areas. TILs, especially CD3+ T cells were associated with the tumor status and tumor grading. BC patients responding to neoadjuvant chemotherapy had significantly more TILs and CD3+ T cells at the TC. The presence of DTCs after NACT was related to CD4+ infiltration at the TC. The dissimilar spatial association of TILs and TIL subtypes with clinicopathological parameters, NACT response and minimal residual disease underlines the necessity of detailed TIL analysis for a better understanding of immune modulatory processes.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor-infiltrating lymphocytes (TILs) are described as an important immune modulator in the tumor microenvironment and are associated with breast cancer (BC) outcome. The spatial analysis of TILs and TIL subtype distribution at the invasive tumor front (ITF) and the tumor center (TC) might provide further insights into tumor progression.
METHODS
METHODS
We analyzed core biopsies from 87 pre-therapeutic BC patients for total TILs and the following subtypes: CD3+, CD4+, CD8+, CD20+ and CD68+ cells in correlation to clinicopathological parameters and disseminated tumor cells (DTCs) in the bone marrow.
RESULTS
RESULTS
TILs and TIL subtypes showed significantly different spatial distribution among both tumor areas. TILs, especially CD3+ T cells were associated with the tumor status and tumor grading. BC patients responding to neoadjuvant chemotherapy had significantly more TILs and CD3+ T cells at the TC. The presence of DTCs after NACT was related to CD4+ infiltration at the TC.
CONCLUSION
CONCLUSIONS
The dissimilar spatial association of TILs and TIL subtypes with clinicopathological parameters, NACT response and minimal residual disease underlines the necessity of detailed TIL analysis for a better understanding of immune modulatory processes.
Identifiants
pubmed: 30717704
doi: 10.1186/s12885-019-5320-2
pii: 10.1186/s12885-019-5320-2
pmc: PMC6360695
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120Références
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
Oral Dis. 1998 Jun;4(2):70-7
pubmed: 9680893
Clin Transl Oncol. 2016 May;18(5):497-506
pubmed: 26459255
Ann Surg Oncol. 2016 Jul;23(7):2242-8
pubmed: 26965699
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
BMC Cancer. 2012 Sep 11;12:403
pubmed: 22963449
Ann Oncol. 2014 Jun;25(6):1128-36
pubmed: 24618153
Clin Cancer Res. 2011 May 1;17(9):2967-76
pubmed: 21415211
BMC Cancer. 2013 Oct 15;13:480
pubmed: 24128322
Ann Oncol. 2012 Sep;23(9):2271-2277
pubmed: 22383680
Cancer Res. 2009 Mar 1;69(5):2000-9
pubmed: 19244125
World J Clin Oncol. 2017 Apr 10;8(2):120-134
pubmed: 28439493
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Clin Cancer Res. 2016 Dec 1;22(23):5747-5754
pubmed: 27189162
Breast Cancer Res. 2016 Jul 29;18(1):78
pubmed: 27473061
BMC Cancer. 2012 May 28;12:190
pubmed: 22640166
Cancer Cell. 2009 Aug 4;16(2):91-102
pubmed: 19647220
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Biol Proced Online. 2018 Jul 01;20:13
pubmed: 29988526
Sci Rep. 2016 May 23;6:26355
pubmed: 27212060
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7529-34
pubmed: 21502514
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Breast Cancer Res Treat. 2012 Apr;132(3):793-805
pubmed: 21562709
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
PLoS One. 2013 Dec 02;8(12):e79775
pubmed: 24312450
Expert Rev Mol Diagn. 2011 Jan;11(1):91-100
pubmed: 21171924
Annu Rev Med. 2013;64:45-57
pubmed: 23121183
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Pol J Pathol. 2017;68(1):26-32
pubmed: 28547977
PLoS One. 2012;7(12):e52796
pubmed: 23300781
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Cancer. 2006 Sep 1;107(5):885-92
pubmed: 16874814
N Engl J Med. 2005 Aug 25;353(8):793-802
pubmed: 16120859
Maedica (Bucur). 2015 Jun;10(2):185-191
pubmed: 28275416
Oncol Rep. 2005 Aug;14(2):425-31
pubmed: 16012726
Cancer Discov. 2011 Jun;1(1):54-67
pubmed: 22039576
Geburtshilfe Frauenheilkd. 1994 Oct;54(10):552-8
pubmed: 8001751
Cancer Res. 1996 Oct 15;56(20):4625-9
pubmed: 8840975
PLoS One. 2013 Jul 18;8(7):e68171
pubmed: 23935856
Biol Chem. 2008 Aug;389(8):1037-41
pubmed: 18979628
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
J Clin Oncol. 2015 Jan 1;33(1):13-21
pubmed: 25092775
Breast Cancer Res. 2014 Nov 29;16(6):488
pubmed: 25432519
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Breast Cancer Res. 2013;15(5):R94
pubmed: 24099325
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Cancer Res. 2011 Apr 1;71(7):2455-65
pubmed: 21459803
Clin Cancer Res. 2006 Oct 1;12(19):5615-21
pubmed: 17020963
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Breast Cancer Res. 2016 Feb 12;18(1):20
pubmed: 26868521
Clin Exp Metastasis. 2016 Oct;33(7):727-39
pubmed: 27449756
Pathol Oncol Res. 2016 Jul;22(3):449-52
pubmed: 26589512
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7
pubmed: 21482773
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Anticancer Res. 2010 May;30(5):1807-13
pubmed: 20592383
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Nature. 2016 Dec 22;540(7634):552-558
pubmed: 27974799
Eur J Cancer. 2011 Jul;47(10):1527-36
pubmed: 21334874
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Arch Pathol Lab Med. 2007;131(1):18-43
pubmed: 19548375
Breast Cancer Res Treat. 2011 Aug;128(3):703-711
pubmed: 20842526
J Thorac Oncol. 2010 Dec;5(12):2024-36
pubmed: 21155185
J Clin Oncol. 2015 Mar 20;33(9):983-91
pubmed: 25534375
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Asian Pac J Cancer Prev. 2015;16(7):2665-9
pubmed: 25854343
Breast Cancer Res Treat. 2014 Apr;144(2):353-60
pubmed: 24554386
Tumour Biol. 2017 Apr;39(4):1010428317695023
pubmed: 28378631
Br J Cancer. 2013 Jan 15;108(1):155-62
pubmed: 23169287
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Natl Cancer Inst. 2005 Feb 2;97(3):188-94
pubmed: 15687361
Breast Cancer Res. 2014 Sep 06;16(5):432
pubmed: 25193543
Clin Cancer Res. 2013 Jan 1;19(1):28-33
pubmed: 23258741
Clin Cancer Res. 2010 Jul 1;16(13):3485-94
pubmed: 20479064
Nat Rev Clin Oncol. 2018 Mar;15(3):129-131
pubmed: 29158590
J Clin Oncol. 2014 Dec 1;32(34):3848-57
pubmed: 25366688
Nat Rev Clin Oncol. 2011 Mar;8(3):151-60
pubmed: 21364688
Cancers (Basel). 2014 Jan 15;6(1):143-52
pubmed: 24434543
PLoS One. 2011;6(7):e22303
pubmed: 21779410
Breast. 2015 Nov;24 Suppl 2:S73-7
pubmed: 26387601
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Cancer Res. 2011 Sep 1;71(17):5670-7
pubmed: 21846824
Anticancer Res. 1998 Nov-Dec;18(6B):4757-64
pubmed: 9891553
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24
pubmed: 15623559
Anticancer Res. 2011 Oct;31(10):3623-8
pubmed: 21965788